Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in primary lung malignancies: a systematic review and meta-analysis with GRADE assessment

View ORCID ProfileDanyal Yarahmadi, Fatemeh Naseri Rad, Ihsaan Patel, Mohammad Yarahmadi, Aida Rashidi, Ali Yarahmadi, Parastou Kordestani Moghadam, Niayesh Naghavi, View ORCID ProfileMohammadsadra Shamohammadi
doi: https://doi.org/10.64898/2026.10.18.26365819
Danyal Yarahmadi
1Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Danyal Yarahmadi
  • For correspondence: Danial78y78{at}gmail.com Msadrashamohammadis{at}gmail.com
Fatemeh Naseri Rad
2Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ihsaan Patel
3School of Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Yarahmadi
4School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aida Rashidi
2Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali Yarahmadi
5School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parastou Kordestani Moghadam
6Department of Nursing and Midwifery, Lorestan University of Medical Sciences, Khorramabad, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Niayesh Naghavi
5School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammadsadra Shamohammadi
1Gastrointestinal and Liver Diseases Research Center, Iran University of Medical Sciences, Tehran, Iran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammadsadra Shamohammadi
  • For correspondence: Danial78y78{at}gmail.com Msadrashamohammadis{at}gmail.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The C-reactive protein–albumin–lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune function. We evaluated its association with survival in primary lung malignancies.

Methods Embase, PubMed, Scopus, and Web of Science were searched from inception to 18 September 2026. Risk of bias was assessed using the Quality In Prognosis Studies tool. Hazard ratios (HRs) were synthesized using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Sensitivity analyses, subgroup analyses, and meta-regression examined robustness and heterogeneity.

Results Eleven studies contributed 13 cohorts to the overall survival (OS) analysis and 8 cohorts from seven studies to a combined recurrence/progression-free survival (RFS/PFS) analysis. Lower CALLY was associated with poorer OS (HR 1.78, 95% CI 1.49–2.12; I²=71.6%) and poorer RFS/PFS (HR 1.60, 95% CI 1.40–1.84; I²=0%). Associations persisted in leave-one-out analyses. No statistically significant subgroup differences were detected. Funnel-plot asymmetry suggested small-study effects for OS and RFS/PFS. Seven studies had moderate and four had high overall risk of bias. The certainty of evidence was rated as low for both OS and RFS/PFS, primarily due to risk of bias, heterogeneity, and endpoint indirectness.

Conclusion Lower CALLY was associated with adverse survival outcomes in the current synthesis. Methodological limitations and variation in biomarker measurement and endpoint definitions restrict interpretation. Prospective validation using standardized measurements and clinically coherent outcomes is needed to establish incremental prognostic value and clinical utility.

Competing Interest Statement

The authors have declared no competing interest.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used only publicly available human data obtained from published studies identified through systematic searches of PubMed, Embase, Scopus, and Web of Science.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Footnotes

  • Email: kparastou{at}yahoo.com

Data Availability

All data produced in the present study are available upon reasonable request to the authors All data produced in the present work are contained in the manuscript

  • Abbreviations

    AUC
    area under the receiver operating characteristic curve
    CALLY
    C-reactive protein–albumin–lymphocyte
    C-index
    concordance index
    CAR
    C-reactive protein-to-albumin ratio
    CI
    confidence interval
    CRC
    colorectal cancer
    CRP
    C-reactive protein
    DLBCL
    diffuse large B-cell lymphoma
    DMFS
    distant metastasis-free survival
    GRADE
    Grading of Recommendations Assessment, Development and Evaluation
    HR
    hazard ratio
    ICI
    immune checkpoint inhibitor
    IQR
    interquartile range
    KM
    Kaplan–Meier
    LA-NSCLC
    locally advanced non-small cell lung cancer
    LC
    lung cancer
    LIPI
    lung immune prognostic index
    LPFS
    locoregional progression-free survival
    mGPS
    modified Glasgow Prognostic Score
    MLR
    monocyte-to-lymphocyte ratio
    MV
    multivariable
    NLR
    neutrophil-to-lymphocyte ratio
    NR
    not reported
    NSCLC
    non-small cell lung cancer
    OS
    overall survival
    PFS
    progression-free survival
    PLR
    platelet-to-lymphocyte ratio
    PNI
    prognostic nutritional index
    PRISMA
    Preferred Reporting Items for Systematic Reviews and Meta-Analyses
    PROSPERO
    International Prospective Register of Systematic Reviews
    PSM
    propensity score matching
    QUIPS
    Quality In Prognosis Studies
    REML
    restricted maximum likelihood
    RFS
    recurrence-free survival
    ROC
    receiver operating characteristic
    RT
    radiotherapy
    SCLC
    small cell lung cancer
    SD
    standard deviation
    SE
    standard error
    TNM
    tumor–node–metastasis
    UV
    univariable.
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
    Back to top
    PreviousNext
    Posted October 20, 2026.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in primary lung malignancies: a systematic review and meta-analysis with GRADE assessment
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in primary lung malignancies: a systematic review and meta-analysis with GRADE assessment
    Danyal Yarahmadi, Fatemeh Naseri Rad, Ihsaan Patel, Mohammad Yarahmadi, Aida Rashidi, Ali Yarahmadi, Parastou Kordestani Moghadam, Niayesh Naghavi, Mohammadsadra Shamohammadi
    medRxiv 2026.10.18.26365819; doi: https://doi.org/10.64898/2026.10.18.26365819
    Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in primary lung malignancies: a systematic review and meta-analysis with GRADE assessment
    Danyal Yarahmadi, Fatemeh Naseri Rad, Ihsaan Patel, Mohammad Yarahmadi, Aida Rashidi, Ali Yarahmadi, Parastou Kordestani Moghadam, Niayesh Naghavi, Mohammadsadra Shamohammadi
    medRxiv 2026.10.18.26365819; doi: https://doi.org/10.64898/2026.10.18.26365819

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Oncology
    Subject Areas
    All Articles
    • Addiction Medicine (638)
    • Allergy and Immunology (917)
    • Anesthesia (350)
    • Cardiovascular Medicine (5000)
    • Dentistry and Oral Medicine (495)
    • Dermatology (428)
    • Emergency Medicine (676)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1690)
    • Epidemiology (16253)
    • Forensic Medicine (36)
    • Gastroenterology (1241)
    • Genetic and Genomic Medicine (7274)
    • Geriatric Medicine (751)
    • Health Economics (1093)
    • Health Informatics (5284)
    • Health Policy (1467)
    • Health Systems and Quality Improvement (1832)
    • Hematology (599)
    • HIV/AIDS (1381)
    • Infectious Diseases (except HIV/AIDS) (16484)
    • Intensive Care and Critical Care Medicine (1203)
    • Medical Education (700)
    • Medical Ethics (156)
    • Nephrology (751)
    • Neurology (7586)
    • Nursing (377)
    • Nutrition (1129)
    • Obstetrics and Gynecology (1295)
    • Occupational and Environmental Health (1040)
    • Oncology (3742)
    • Ophthalmology (1093)
    • Orthopedics (409)
    • Otolaryngology (465)
    • Pain Medicine (501)
    • Palliative Medicine (143)
    • Pathology (721)
    • Pediatrics (1858)
    • Pharmacology and Therapeutics (755)
    • Primary Care Research (786)
    • Psychiatry and Clinical Psychology (6124)
    • Public and Global Health (9986)
    • Radiology and Imaging (2529)
    • Rehabilitation Medicine and Physical Therapy (1516)
    • Respiratory Medicine (1268)
    • Rheumatology (658)
    • Sexual and Reproductive Health (804)
    • Sports Medicine (595)
    • Surgery (803)
    • Toxicology (109)
    • Transplantation (318)
    • Urology (307)